![]() |
|||||||||||||||||
![]() |
|||||||||||||||||
![]() ![]() ![]() |
![]() |
|
|||||||||||||||
![]() |
![]() |
MATERIAL SAFETY DATA SHEET - INFECTIOUS SUBSTANCES SECTION I - INFECTIOUS AGENT NAME: Epstein-Barr virus SYNONYM OR CROSS REFERENCE: EBV, infectious mononucleosis (IM), glandular fever, Burkitt's lymphoma (BL), Nasopharangeal carcinoma (NPC), Human herpes virus (HHV) 4 CHARACTERISTICS: Double-stranded linear DNA, 120-150 nm diameter, enveloped, icosahedral; types A and B; Herpesviridae (Gammaherpesvirinae) SECTION II - HEALTH HAZARD PATHOGENICITY: Infectious mononucleosis - acute viral syndrome with fever, sore throat, splenomegaly and lymphadenopathy; one to several weeks, rarely fatal/ Burkitt's lymphoma - monoclonal tumour of B cells, usually involving children jaw involvement is common; AIDS patients( 25% -30% are EBV related) / Nasopharangeal carcinoma - malignant tumour of epithelial cells of the nasopharynx involving adults between 20 and 40 years EPIDEMIOLOGY: EBV infects 80 - 90% of all adults world wide; mononucleosis is common in early childhood worldwide, typical disease occurs in developed countries mainly in young adults; Burkitt's tumour is worldwide but hyperendemic in highly malarial areas such as tropical Africa; carcinoma is worldwide but highest in Southeast Asia and China, especially in males; EBV plays important pathogenic role in approximately 97% of BL cases in Africa and Papua New Guinea HOST RANGE: Humans INFECTIOUS DOSE: Not known MODE OF TRANSMISSION: Mononucleosis - person-to-person by oropharyngeal route via saliva, possible spread via blood transfusion (not important route); Burkitt's lymphoma - primary infection occurs early in life or involves immunosuppression and reactivation of EBV later, malaria an important co-factor; NPC infection occurs in early life and reactivation later with epithelial invasion INCUBATION PERIOD: IM - 4-6 weeks; BL - 2-12 years from primary infection, shorter in AIDS patients; NPC - unknown COMMUNICABILITY: IM - prolonged period, up to 1 year or more, 15-20% of EBV antibody-positive adults are oropharyngeal carriers; tumours are not communicable SECTION III - DISSEMINATION RESERVOIR: Humans ZOONOSIS: None VECTORS: None SECTION IV - VIABILITY DRUG SUSCEPTIBILITY: Not applicable SUSCEPTIBILITY TO DISINFECTANTS: Susceptible to disinfectants - 1% sodium hypochlorite, 70% ethanol, glutaraldehyde, formaldehyde PHYSICAL INACTIVATION: Inactivated by heat (50-60° C for at least 30 min) SURVIVAL OUTSIDE HOST: Survives at room temp for a few days, 2-3 days at refrigeration temperature, -70° C many years SECTION V - MEDICAL SURVEILLANCE: Monitor for symptoms; confirm serologically (heterophile antibody titre) positive in 85-90% of IN patients FIRST AID/TREATMENT: No specific treatment; steroids may be of some value in severe cases IMMUNIZATION: Subunit vaccines against EBV are in trial stage PROPHYLAXIS: None SECTION VI - LABORATORY HAZARDS LABORATORY-ACQUIRED INFECTIONS: 2 reported cases of EB infection up to 1976 SOURCES/SPECIMENS: Clinical specimens - nasopharyngeal secretions, blood PRIMARY HAZARDS: Ingestion, accidental parenteral inoculation, droplet exposure of the mucous membranes, inhalation of concentrated aerosolized materials SPECIAL HAZARDS: None SECTION VII - RECOMMENDED PRECAUTIONS CONTAINMENT REQUIREMENTS: Biosafety level 2 practices, containment equipment and facilities for activities utilizing known or potentially infectious clinical materials or cultures PROTECTIVE CLOTHING: Laboratory coat; gloves when direct contact with infectious materials is unavoidable OTHER PRECAUTIONS: Procedures that are likely to generate aerosols should be conducted in a biosafety cabinet SECTION VIII - HANDLING INFORMATION SPILLS: Allow aerosols to settle; wear protective clothing; gently cover spill with paper towel and apply 1% sodium hypochlorite, starting at perimeter and working towards the centre; allow sufficient contact time (30 min) before clean up DISPOSAL: Decontaminate before disposal; steam sterilization, chemical disinfection, incineration STORAGE: In sealed containers that are appropriately labelled SECTION IX - MISCELLANEOUS INFORMATION Date prepared: March, 2001 Prepared by: Office of Laboratory Security, PHAC Although the information, opinions and recommendations contained in this Material Safety Data Sheet are compiled from sources believed to be reliable, we accept no responsibility for the accuracy, sufficiency, or reliability or for any loss or injury resulting from the use of the information. Newly discovered hazards are frequent and this information may not be completely up to date. Copyright © [Material Safety Data Sheets - Index]
|
![]() |
|||
![]() |
Last Updated: 2001-05-15 | ![]() |